$INCY

Tray Thomas sold $264K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,639 shares of INCYTE CORP (INCY) at $100.00 ($0.26M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published Jun 8, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, execution date (June 4), and that it was conducted under a pre-arranged Rule 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental trading signal for INCY.

03

What to watch

The article provides only the sale details (size/price/plan) and no context on total compensation, tax-motivated selling, or whether other insiders are selling/buying concurrently.

Relevance 3/10Novelty 2/10Timing: Filed June 8; sale executed June 4.

Background

The article reports an SEC Form 4 insider transaction for Incyte, filed via EDGAR.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows Tray Thomas (principal accounting officer) sold 2,639 shares at $100/share under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still monitor for clustering of sales.

Key entities

  • INCY

    Incyte Corp; subject of the Form 4 insider sale disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.